Pharmos (PARS) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Pharmos (PARS)

An SI Board Since October 1998

Posts	SubjectMarks	Bans	Symbol
1386	42	0	PARS

Emcee: Dr. John M. de Castro	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
911	Arnie, They are indeed figuring out the results. May take a few months. Expect	Zvi Steinberg	-	10/4/1999
910	Cacaito: Thanks for the link. One fascinating comment made is that Phase 2 of t	arnie h	-	10/4/1999
909	Cacaito, thanks -- excellent link! Zvi	Zvi Steinberg	-	10/4/1999
908	Please check for a positive mention of Pharmos: signalsmag.com I do no want a	Cacaito	-	10/4/1999
907	Dave, very well said. They need a deal, for better or worse. Something to move	LemonHead	-	10/4/1999
906	<With this stock, whenever bad news is on the horizon, the level of short se	LLCF	-	10/3/1999
905	<Is there no good news out there?> another response. Stephen: With this s	arnie h	-	10/3/1999
904	<Is there no good news out there? > Well, we're still waiting on TH	LLCF	-	9/30/1999
903	I can't believe how quiet this thread got all of a sudden. Is there no goo	Stephen D. Wilson	-	9/30/1999
902	Genesis partners, a venture capital fund backed by CIBC Oppenheimer and Eddy sh	LLCF	-	9/14/1999
901	The length of the study depends on the number of centers. And how fast each cen	yosi s	-	9/9/1999
900	<PARS results early next year - cohort 3 enrollment finished mid-summer, the	arnie h	-	9/9/1999
899	PARS results early next year - cohort 3 enrollment finished mid-summer, then si	Jesse Schulman	-	9/9/1999
898	What I try to point out is that cohort 3 total mortality is lower than 2. So I	yosi s	-	9/8/1999
897	Dr. John: As I recall, placebo had lower than usual mortality in cohorts 1 and	arnie h	-	9/8/1999
896	Cohort 3 mortality data encompasses both HU-211 treated subjects and placebo tr	Dr. John M. de Castro	-	9/8/1999
895	I keep on hearing that total mortality in cohort 3 is very favorable. I expect	yosi s	-	9/8/1999
894	abcnews.go.com	yosi s	-	9/8/1999
893	ama-assn.org Abstracts - September 8, 1999	yosi s	-	9/8/1999
892	Dr. John: Super review. Thanks for posting. I especially liked the last sentenc	arnie h	-	9/7/1999
891	New ophthalmic agents offer convenience and other advantages over older drugs.	Dr. John M. de Castro	-	9/7/1999
890	Lotemax main indication is in Cataract surgery.	yosi s	-	9/4/1999
889	Dr John: <Preoperative and postoperative medications used for cataract surge	arnie h	-	9/4/1999
888	When all is said and done. Pharmos came out with a good safe products, ie, Lote	yosi s	-	9/3/1999
887	Preoperative and postoperative medications used for cataract surgery. Rowen S,	Dr. John M. de Castro	-	9/3/1999

Go to reply# or date (mm/dd/yy):